Nivolumab for lung cancer – pro
Nivolumab is a fully human IgG4 monoclonal antibody developed by Ono Pharmaceutical and Medarex for the treatment of cancer. Nivolumab acts as an immunomodulator by blocking ligand activation of the programmed cell death 1 (PD-1) receptor on activated T cells. Nivolumab is a fully human IgG4 monoclonal antibody developed by Ono Pharmaceutical and Medarex for the treatment of cancer. Nivolumab acts as an immunomodulator by blocking ligand activation of the programmed cell death 1 (PD-1) receptor on activated T cells. In the United States, OPDIVO, in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
Tivzi, NA, Mazières, J, Planchard, D et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015; (published online Feb 20.)http://dx.doi.org/10.1016/S1470-2045(15)70054-9.
Prescribing Information, Nivolumab 2023
NCCN, Non-small cell lung cancer, NSCL-F, 2, 2023